Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations

Polygenic risk scores (PRS) have improved in predictive performance supporting their use in clinical practice. Reduced predictive performance of PRS in diverse populations can exacerbate existing health disparities. The NHGRI-funded eMERGE Network is returning a PRS-based genome-informed risk assessment to 25,000 diverse adults and children. We assessed PRS performance, medical actionability, and potential clinical utility for 23 conditions. Standardized metrics were considered in the selection process with additional consideration given to strength of evidence in African and Hispanic populations. Ten conditions were selected with a range of high-risk thresholds: atrial fibrillation, breast cancer, chronic kidney disease, coronary heart disease, hypercholesterolemia, prostate cancer, asthma, type 1 diabetes, obesity, and type 2 diabetes. We developed a pipeline for clinical PRS implementation, used genetic ancestry to calibrate PRS mean and variance, created a framework for regulatory compliance, and developed a PRS clinical report. eMERGEs experience informs the infrastructure needed to implement PRS-based implementation in diverse clinical settings.

[1]  Melissa L. Habrat,et al.  Returning integrated genomic risk and clinical recommendations: the eMERGE study. , 2023, Genetics in medicine : official journal of the American College of Medical Genetics.

[2]  J. Kaprio,et al.  Systematic comparison of family history and polygenic risk across 24 common diseases , 2022, medRxiv.

[3]  Judy H. Cho,et al.  Genome-wide polygenic score to predict chronic kidney disease across ancestries , 2022, Nature Medicine.

[4]  M. Gladwin,et al.  The Value of Rare Genetic Variation in the Prediction of Common Obesity in European Ancestry Populations , 2022, Frontiers in Endocrinology.

[5]  J. Chang-Claude,et al.  Polygenic risk score for defining personalized surveillance intervals after adenoma detection and removal at colonoscopy. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  Alicia R. Martin,et al.  Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps , 2021, Nature Medicine.

[7]  Matthew S. Lebo,et al.  Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations , 2022, Genome Medicine.

[8]  Max W. Y. Lam,et al.  Improving Polygenic Prediction in Ancestrally Diverse Populations , 2021, Nature Genetics.

[9]  S. A. Lambert,et al.  The Polygenic Score Catalog: an open database for reproducibility and systematic evaluation , 2020, medRxiv.

[10]  C. Kooperberg,et al.  Improving reporting standards for polygenic scores in risk prediction studies , 2020, Nature.

[11]  P. Elliott,et al.  Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease. , 2020, JAMA.

[12]  C. Weinberg,et al.  Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries , 2019 .

[13]  M. Feldman,et al.  Analysis of polygenic risk score usage and performance in diverse human populations , 2019, Nature Communications.

[14]  Alicia R. Martin,et al.  Clinical use of current polygenic risk scores may exacerbate health disparities , 2019, Nature Genetics.

[15]  A. Toland,et al.  Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer , 2019, Journal of personalized medicine.

[16]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[17]  E. Topol,et al.  The personal and clinical utility of polygenic risk scores , 2018, Nature Reviews Genetics.

[18]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[19]  Po-Ru Loh,et al.  Multi-ethnic polygenic risk scores improve risk prediction in diverse populations , 2016, bioRxiv.

[20]  Christopher R. Gignoux,et al.  Human demographic history impacts genetic risk prediction across diverse populations , 2016, bioRxiv.

[21]  Shane A. McCarthy,et al.  Reference-based phasing using the Haplotype Reference Consortium panel , 2016, Nature Genetics.

[22]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[23]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[24]  Wendy A. Wolf,et al.  The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies , 2011, BMC Medical Genomics.

[25]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[26]  B. Helfand,et al.  Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools. , 2019, Clinical chemistry.

[27]  Benjamin Neale,et al.  Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults Implications for Primary Prevention , 2019 .